[144] CORCEPT THERAPEUTICS INC SEC Filing

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) Form 144 filing reports a proposed sale of 5,000 common shares through Stifel Nicolaus & Co. with an aggregate market value of $415,550.00, planned for 10/01/2025 on NASDAQ. The filing states these 5,000 shares were acquired the same day (10/01/2025) by stock option exercise and paid in cash.

The filing also lists prior sales by the same person, Joseph D. Lyon, totaling 15,000 shares sold on 07/01/2025, 07/17/2025, 07/18/2025, 08/01/2025, and 09/02/2025 with reported gross proceeds for each transaction. The filer certifies they are not aware of undisclosed material adverse information about the issuer.

Positive

• Regulatory compliance: Form 144 provides required disclosure details including broker, acquisition method, payment, and prior sales.
• Transparency: Filing includes insider certification that no undisclosed material adverse information is known.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale filing; modest share amount relative to total outstanding shares, providing regulatory transparency.

The Form 144 documents a proposed sale of 5,000 common shares acquired by option exercise on the same day, with an aggregate market value of $415,550 and an intended sale date of 10/01/2025 through Stifel Nicolaus on NASDAQ. Recent historical sales by the same person are disclosed, demonstrating ongoing disposition activity. Relative to the issuer's stated 105,370,000 shares outstanding, the reported proposed sale is immaterial in percentage terms, and the filing primarily serves a compliance and disclosure function rather than signaling a material shift in ownership or control.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 disclosure requirements and includes the insider certification; no material corporate governance concerns evident.

The document includes required details: acquisition date, nature of acquisition (stock option exercise), payment method (cash), broker name and address, and prior sales in the past three months. The signer affirms no undisclosed material adverse information exists. Based on the supplied figures, there is transparency around insider trading activity but no indication of regulatory noncompliance or governance red flags within the content provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Co. Inc. 501 N. Broadway St Louis MO 63102	5000	415550.00	105370000	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Stock Option Exercise	Corcept Therapeutics Inc.			5000	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/01/2025	100	7350.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	3877	284864.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/18/2025	200	14680.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/01/2025	5823	393128.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	09/02/2025	5000	351248.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for CORT cover?

The notice covers a proposed sale of 5,000 common shares of Corcept Therapeutics (CORT).

When and where is the proposed sale scheduled?

The sale is scheduled for 10/01/2025 through Stifel Nicolaus & Co. on NASDAQ.

How were the 5,000 shares acquired?

The 5,000 shares were acquired on 10/01/2025 by stock option exercise and paid in cash.

Has the seller previously sold shares recently?

Yes. Joseph D. Lyon sold shares on 07/01/2025 (100), 07/17/2025 (3,877), 07/18/2025 (200), 08/01/2025 (5,823), and 09/02/2025 (5,000) with listed gross proceeds.

What is the aggregate market value reported for the proposed sale?

The filing reports an aggregate market value of $415,550.00 for the 5,000 shares.